Trinity Biotech said life sciences supply is no longer a core part of its strategy and will use the sale proceeds to significantly reduce its debt.
Read more: Trinity Biotech sells life sciences supply firm to Biosynth for $30m
Trinity Biotech said life sciences supply is no longer a core part of its strategy and will use the sale proceeds to significantly reduce its debt.
Read more: Trinity Biotech sells life sciences supply firm to Biosynth for $30m